Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. alleging securities fraud that affected investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates, overstated the quality of its supply chain and partners, and that these statements were materially false and misleading [2]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 21, 2025, to August 28, 2025, Telix Pharmaceuticals materially overstated its progress with prostate cancer therapeutic candidates [3]. - It is claimed that the company also overstated the quality of its supply chain and partners, leading to false and misleading statements about its business operations and prospects [3]. Group 2: Class Action Details - Shareholders who purchased shares of TLX during the class period are encouraged to register for the class action, with a deadline set for January 9, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress with prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. alleging securities fraud that affected investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates, overstated the quality of its supply chain and partners, and that these statements were materially false and misleading [2]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. for alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates [2]. - It is alleged that the quality of Telix's supply chain and partners was materially overstated by the defendants [2]. - As a result of these misrepresentations, statements about Telix's business, operations, and prospects were deemed materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited and certain officers for alleged violations of federal securities laws during the Class Period from February 21, 2025, to August 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased or acquired Telix securities during the specified Class Period [2]. - The complaint alleges that the defendants made false and misleading statements regarding Telix's progress with prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit can review the complaint and are encouraged to contact the law firm for further information [4]. - A deadline of January 9, 2026, has been set for investors to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from February 21, 2025, to August 28, 2025 [3]. - Allegations include that Telix Pharmaceuticals materially overstated its progress with prostate cancer therapeutic candidates and the quality of its supply chain and partners [3]. - As a result of these alleged misstatements, the company's statements about its business, operations, and prospects were deemed materially false and misleading [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by the deadline of January 9, 2026, to potentially be appointed as lead plaintiff [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 9, 2026 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress with prostate cancer therapeutic candidates and the quality of its supply chain [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6]. - The lawsuit alleges that Telix made materially false and misleading statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by January 9, 2026, to serve as lead plaintiff, representing other class members [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].